This is a very untypical genotype–phenotype combination and there should be further molecular assessment according to the cIMPACT guidelines (Louis et al. 2020; Gonzalez Castro and Wesseling 2021) including copy number profiling (CNP) to further characterize such cases and to assess, if the underlying biology is that of glioblastoma IDH wild type. This evidence concerns the gene IDH2 and glioblastoma.